Stem cell aging in adult progeria by unknown
REVIEW Open Access
Stem cell aging in adult progeria
Hoi-Hung Cheung1, Duanqing Pei2 and Wai-Yee Chan1,3*
Abstract
Aging is considered an irreversible biological process and also a major risk factor for a spectrum of geriatric
diseases. Advanced age-related decline in physiological functions, such as neurodegeneration, development of
cardiovascular disease, endocrine and metabolic dysfunction, and neoplastic transformation, has become the
focus in aging research. Natural aging is not regarded as a programmed process. However, accelerated aging
due to inherited genetic defects in patients of progeria is programmed and resembles many aspects of
natural aging. Among several premature aging syndromes, Werner syndrome (WS) and Hutchinson–Gilford
progeria syndrome (HGPS) are two broadly investigated diseases. In this review, we discuss how stem cell
aging in WS helps us understand the biology of aging. We also discuss briefly how the altered epigenetic
landscape in aged cells can be reversed to a “juvenile” state. Lastly, we explore the potential application of
the latest genomic editing technique for stem cell-based therapy and regenerative medicine in the context of aging.
Keywords: Werner syndrome, Stem cells, Aging, WRN
Werner syndrome: clinical features, genetics,
and pathogenesis
Werner syndrome (WS) was first described by Otto
Werner in 1904. Patients of WS are characterized by
premature aging which are clinically apparent during
20–30 years old. WS patients show abnormal physical
development such as a bird-like face, short stature, and
slender limbs. They also display a high-pitched voice, re-
markable loss and graying of hair, and scleroderma-like
skin changes. Other common clinical presentations in-
clude bilateral cataracts, type 2 diabetes mellitus, hypo-
gonadism (with reduced fertility), skin ulcers, premature
arteriosclerosis, osteoporosis, and cancer predisposition
[1, 2]. Ninety percent of WS is linked to mutations on
WRN, a member of the RecQ family responsible for
stable genome maintenance. Owing to autosomal reces-
sive inheritance, biallelic mutation on WRN is patho-
genic. The frequency of WS is estimated to be 1 in
20,000–40,000 in Japanese population and slightly lower
in the world [3, 4].
The pathogenesis of WS due to loss of the WRN pro-
tein has been well elucidated by the biochemical nature
of the WRN helicase. As a multifunctional nuclear pro-
tein, WRN is an ATP-dependent 3′–>5′ helicase and
exonuclease. It unwinds secondary DNA structure such
as tetraplex DNA and Holliday junction and resolves
stalled replication fork during DNA replication. More
importantly, WRN participates in multiple DNA repair
pathways such as base excision repair, non-homologous
end joining, and homologous recombination [5]. In
addition to DNA replication and DNA repair, WRN is
also involved in telomere maintenance. Telomere repli-
cation and protection are pivotal for maintaining gen-
ome integrity and stability and also serve as an aging
marker. Accelerated aging due to loss of WRN function
is well explained by its biochemical functions in relation
to DNA replication, repair, recombination, and telomere
maintenance [6]. From a developmental point of view,
progressive cell loss due to apoptosis, cell cycle arrest, or
senescence in actively dividing cells may be a conse-
quence of WRN loss. Since WS is an adult onset disease,
genetic instability accumulates with age. The manifest-
ation of premature aging phenotypes becomes apparent
when accumulated DNA damages are not properly
repaired and WRN-deficient cells fail to maintain their
genomic integrity [7]. WS cells thus, while being diag-
nosed and biopsied, display a variegated translocation
* Correspondence: chanwy@cuhk.edu.hk
1CUHK-CAS GIBH Joint Research Laboratory on Stem Cell and Regenerative
Medicine, School of Biomedical Sciences, Faculty of Medicine, The Chinese
University of Hong Kong, Shatin, Hong Kong S.A.R., China
3The Chinese University of Hong Kong, Room G03A, Lo Kwee-Seong
Intergrated Biomedical Science Building, Shatin, N.T., Hong Kong S.A.R., China
Full list of author information is available at the end of the article
© 2015 Cheung et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cheung et al. Cell Regeneration  (2015) 4:6 
DOI 10.1186/s13619-015-0021-z
mosaicism in skin fibroblasts and shorter telomere
length [8]. WS fibroblasts also display premature senes-
cence and accelerated telomere loss. From the view of
pathogenesis, accumulation of deleterious DNA muta-
tions and persistence of genomic instability eventually
attain a pathogenic threshold to be reflected in different
phenotypes - premature aging in many of the mesenchy-
mal cell types and acquisition of neoplasm [9].
Stem cell aging in connection with segmental
progeria in Werner syndrome
Progeroid syndromes such as WS and Hutchinson–
Gilford progeria syndrome (HGPS) show phenotypes
of accelerated aging resembling normal aging, such as
the development of bilateral cataract, aging skin, gray-
ing and loss of hair, cardiovascular disease, and osteo-
porosis [1]. However, they are segmental in nature,
meaning that only a specific category of tissues is predom-
inantly affected. For WS, age-related dementia and cogni-
tive impairment are rarely reported, leading to the
hypothesis that progeroid syndromes are not seemingly an
accelerated mode of aging. Nevertheless, how de novo
mutation in, for instance, WRN, leads to segmental aging
remains to be answered. A number of models of aging
have been described to explain the aging mechanisms in
stem cells as well as in model animals. These models are
based on the molecular pathways known to regulate lon-
gevity, reactive oxygen species (ROS) production, mito-
chondrial function, telomere protection, cell cycle control
and senescence, protein homeostasis, and systemic inflam-
mation [10]. In WS, specific pathways are amplified and
connected to the aging program leading to accelerated but
lineage-specific aging. Our discussions below focus on the
telomere function and epigenetic regulation in connection
with stem cell aging in progeroid syndromes.
Telomere dysfunction as a hallmark of premature
aging in WS cells
The hypothesis of telomere erosion as a chronological
aging marker has been well documented by many inves-
tigations linking the telomere lengths to the biological
age. A population in advanced age has a shorter average
telomere length than younger groups, although varia-
tions exist within each age group [11]. In telomerase-
null mice, shorter telomeres are found after several
generations of interbreeding. Degenerated phenotypes
are observed in late-generation, telomerase-null mice.
However, reconstitution of telomerase can rescue these
phenotypes, suggesting the telomere length as a patho-
logical factor for aging [12]. Telomere is not only a bio-
logical clock counting the number of cell divisions but
also a protective structure for ensuring genomic integrity
and stability. Specifically, the telomere is highly orga-
nized and orchestrated by telomere-binding proteins
called shelterin [13]. Loss of telomeric DNA or failure of
telomere protection elicits telomere dysfunction, which
subsequently induces cell cycle arrest, apoptosis, or sen-
escence [14]. Telomere dysfunction-induced cell cycle
arrest in stem cells serves as a protective mechanism to
prevent propagation of genetically unstable daughter
cells from passing on [15]. In many adult stem cells such
as mesenchymal stem cells (MSC) and muscle stem
cells, telomerase activity is restricted, indicating a finite
number of divisions allowed. The adult stem cell pool is
kept at a balanced quiescent and proliferative state in re-
sponse to signals of differentiation or regeneration. The
stem cell pool is believed to exhaust with age, thus giv-
ing less regenerative potential [16]. In laboratory mice,
the longest telomeres are found in stem cell compart-
ments requiring active proliferation such as hair follicle
and small intestine stem cells [16].
How the WRN-deficient progeroid stem cells become
depleted remains a challenging question to answer,
mainly because adult stem cells from WS are difficult to
acquire. A comparison of the in vivo telomere length
from a cohort of WS patients with normal individuals
demonstrates accelerated telomere attrition in muscles
and skins [17]. Depletion of WRN protein in normal
fibroblasts also shows a similar result, leading to the
hypothesis that telomere dysfunction due to WRN defi-
ciency is the primary cause for WS pathophysiology
[18]. The mouse model for WS with Wrn deletion, how-
ever, is not sufficient to recapitulate the classical features
of WS in human [19]. Such species-specific difference
can be ascribed to the fact that laboratory mice possess
a longer telomere reserve than human. In support of this
notion, Wrn knockout mice in the background of critic-
ally short telomeres (G4-G6 Terc−/−Wrn−/−), but not in
mice with normal telomeres (Terc+/−Wrn−/−), display
aging phenotypes reminiscent of human WS [20]. How-
ever, WRN may not be an essential factor for telomere
replication because telomerase-immortalized WS cells
can extend the telomere length without inducing telo-
mere dysfunction and senescence [21].
The role of WRN in telomere maintenance
The WRN protein plays a diverse role in protecting gen-
ome stability through interacting with different proteins
in several pathways (refer to review by Bohr et al.) [5].
The current view suggests that WRN interacts with
shelterin proteins to resolve G-quadruplex and Holliday
junction structures in addition to aiding repair of DNA
breaks during DNA synthesis [6, 7, 22]. G-quadruplex
structures are common when DNA polymerase is syn-
thesizing the G-rich, single-stranded D-loop found at
telomeres. Consistent with this notion, WRN-depleted
cells show defective synthesis at the lagging strand of
sister telomeres perhaps due to the failure to resolve
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these structures at telomeres [23]. Eventually, acceler-
ated and progressive telomere loss is found in WS cells,
particularly in adult stem cells which are required for
continuously repairing damaged tissues throughout life.
Using redifferentiated stem cells derived from WS in-
duced pluripotent stem cells (iPSCs), telomere dysfunc-
tion and sister telomere loss at the lagging strand are
also observed in MSC [24]. Interestingly, redifferentiated
neural progenitor cells are not affected, suggesting a
lineage-specific aging mechanism in relation to the telo-
mere function. Many questions remain open as to how
different adult stem cells in WS, like hematopoietic stem
cell (HSC), hair follicle and dermal stem cells, muscle
and cardiovascular stem cells, and even germ cells, are
selectively affected by WRN loss. One possible explan-
ation for the segmental aging mechanism in progeroid
syndrome is the differential telomerase activity in vari-
ous adult stem cells. Telomerase activity is detected in
germ cells and adult stem cells such as neural stem cells
and HSC but almost absent in MSC. Telomerase is
highly expressed in embryonic stem cells and iPSC as
well as in many cancers [25]. In support of this, iPSCs
reprogrammed from WS fibroblasts have normal telo-
mere length that prevent cells from entering senescence.
Differentiated cells, including MSC and fibroblasts, how-
ever, become senescent prematurely whereas they can be
rescued by ectopic expression of telomerase [24, 26]. There-
fore, telomerase may be a factor counteracting the telomere
loss/dysfunction in the absence of the WRN helicase.
Aging-associated epigenetic alterations in normal
aging and progeroid syndromes
Epigenetic modifications on DNA and histones change
with age and vary in different cell types, disease states
(e.g., cancers), and developmental and differentiating
stages [27]. Epigenetic marks that link to aging include
gain of H3K4 and H4K20 trimethylation, H4K16 acetyl-
ation, and decrease in H3K9 and H3K27 trimethylation
(Fig. 1a) [28]. H4K20 trimethylation is a marker for con-
stitutive heterochromatin. Increase of H4K20 trimethyla-
tion is found in aging tissues of rats and also in patients
of HGPS [29, 30]. Epigenetic changes on histone in WS
are largely unknown. A recent report suggests that
heterochromatin alteration, as reflected by global loss of
H3K9 trimethylation and reduction of SUV39H1 (protein
that trimethylates H3K9) and HP1α, is found in WRN
knockout cells [31]. The group concludes heterochroma-
tin disorganization is a potential determinant of prema-
ture aging in WRN-deficient cells.
DNA methylation is also drifted in aged cells. Globally,
hypomethylation is found at various organs/cell types
with advanced age, for examples, blood and dermal fi-
broblasts. Repetitive sequences such as Alu and LINE-1
show decreased 5mC content with age, suggesting a
mechanistic link to the increased genomic instability due
to the loss of global methylation [32]. However, some
locus-specific regions, especially for those at CpG
islands, show hypermethylation as cells age [33]. Some
of the hypermethylated genes are putative tumor
Fig. 1 Aging-associated epigenetic changes on histone modifications. a In aged somatic and stem cells, chromatin is progressively changed.
H3K4me3, H4K20me3, and H4K16ac are increased whereas H3K9me3, H3K27me3, and H3K9ac are decreased. Chromatin remodeling proteins
(e.g., HP1α and NuRD) and DNA methylation are also decreased globally (not shown). Changes of chromatin structure and organization affect
transcriptional activity and genomic stability related to aging. b SIRT1 and SIRT6 are important aging regulators. SIRT1 deacetylates H3K9 and
H4K16 and increases H3K9me3 through SUV39H1. SIRT6 also deacetylates H3K9 at telomeric regions. Hyperacetylation of telomeric H3K9 impairs
association of the WRN protein with telomeres, hence, leading to premature aging
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suppressor genes, extrapolating that epigenetic silencing
is another risk factor for increased neoplastic events in
elderly people. By profiling a number of WS and HGPS
patients, aberrant DNA methylation profile is detected.
For WS, differential methylation on CpG sites is located
in genes enriched for the IKB kinase/NF-kappaB signal-
ing and proteinaceous extracellular matrix formation
[34]. These candidate genes may be involved in the
phenotypic changes observed during premature aging.
Interestingly, WRN itself is also controlled by epigenetic
regulation. Epigenetic downregulation of the WRN gene
is found in many age-related diseases, e.g., cataract and
cancer [35, 36].
Unlike genetic mutations, epigenetic modifications are
reversible, raising the question of whether aging and
longevity can be changed if we are able to change the
age-associated epigenome. A family of genes known to
promote longevity are actually enzymes for epigenetic
modifications. The sirtuin gene family plays a critical
role in regulating aging. Among the seven mammalian
sirtuin genes, SIRT1, SIRT3, and SIRT6 have been shown
to improve health through regulating diverse processes
[37]. Here we briefly discuss the roles of SIRT1 and
SIRT6 in stem cells and aging.
As a histone deacetylase, SIRT1 not only deacetylates
H4K16 and H3K9 but also regulates the histone methyl-
transferase SUV39H1 during heterochromatin formation
[38]. Loss of SIRT1 reduces H3K9 trimethylation and
impairs localization of heterochromatin protein 1 (HP1),
an epigenetic alteration associated with aging. Although
Sirt1 overexpression in mice does not increase longevity,
it does improve healthy aging such as wound healing
and reduced incidence of cancer [39]. In another study,
Sirt1 overexpression specifically in the brain extends life-
span through upregulation of Ox2r by cooperation with
Nkx2-1 [40]. In addition to the epigenetic regulatory
role, Sirt1 also participates in repairing DSB in response
to oxidative stress and helps to combat genomic instabil-
ity and age-dependent transcriptional changes [41]. The
role of SIRT1 in regulation of adult stem cell aging and
homeostasis is evident. SIRT1-deleted young HSCs show
skewed differentiation with reduced lymphoid compart-
ment, anemia, and expression pattern similar to aged
HSCs [42]. In human MSC derived from various adult
tissues, SIRT1 demonstrates a beneficial effect on long-
term growth and differentiation potential [43, 44]. Be-
cause SIRT1 is able to delay premature senescence, it
also plays a role in progeria. Lamin A, the mutant form
causing laminopathy-based premature aging, interacts
with and activates Sirt1. Such interaction is interrupted
in progeroid cells, leading to prominent decline of adult
stem cells in the progeria mouse model [45]. For WS,
expression and localization of WRN is modulated by
SIRT1 and PML [46]. SIRT1 is reported to deacetylate
WRN [47]. Acetylation of the WRN protein enhances its
stability by inhibiting ubiquitination [48]. SIRT1 affects
translocation of the WRN protein from nucleolus to
nucleoplasm when DNA repair is required [49].
SIRT6, another important member of the sirtuin fam-
ily, has other unique biological functions. SIRT6 expres-
sion declines significantly in the aged brain, which is
associated with increased H3K9 acetylation [50]. De-
creased SIRT6 expression is also found in HGPS and
senescent cells but unknown for WS cells [51]. Sirt6
knockout mice exhibit premature aging and develop-
mental abnormalities including profound lymphopenia
and metabolic defects [52]. On the other hand, overex-
pression of Sirt6 increases lifespan in male but not fe-
male mice. Transgenic male mice have a lower serum
level of IGF1, higher level of IGF-binding protein 1, and
altered phosphorylation levels of major components of
IGF1 signaling [53]. Restoring SIRT6 expression in
HGPS cells impedes premature senescence and forma-
tion of dysmorphic nuclei [51]. SIRT6 is a histone H3K9
deacetylase that maintains repressive telomeric chroma-
tin. Repressive heterochromatin at telomeres is an epi-
genetic mechanism for silencing telomere-proximal
genes, which is disrupted in the absence of SIRT6 [54].
Mechanically, SIRT6 specifically associates with telo-
meres where it deacetylates H3K9 which is required for
stable association with WRN. SIRT6-depleted cells show
telomere dysfunction with premature cellular senescence
that resembles WS cells [55]. Besides the role in telo-
mere function, SIRT6 also helps maintain genomic sta-
bility and regulates metabolic homeostasis, another two
hallmarks of aging [56]. In summary, SIRT1 and SIRT6
are the most well-known Sir2 orthologs that contribute
to aging partially through epigenetic regulation of the
“aging” epigenome (Fig. 1b).
Reprogramming aging epigenome for
regenerative medicine
The epigenetic makeup not only becomes changed with
aging but also defines cell identity during development
and stem cell differentiation. Research from the last dec-
ade underscores the reversibility and plasticity of chan-
ging cell fates through epigenetic reprogramming [28].
This is achieved through resetting the epigenome by
transferring a differentiated somatic nucleus to enucle-
ated egg using somatic cell nuclear transfer technique or
by expressing pluripotency-associated transcription fac-
tors (OCT4, SOX2, KLF4, and c-MYC or variant combi-
nations) [57]. Insights gained from the reprogramming
experiments raise the feasibility of erasing epigenetic
memories associated with aging to restore a “juvenile”
state. The epigenome of iPSC, in fact, is highly similar to
embryonic stem cells (ESC) and capable of generating a
variety of adult stem cells with regenerative capacity
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[58]. Epigenetic reprogramming is achieved initially
using embryonic somatic cells [59]. Subsequently, som-
atic cells from more aged donors can be reprogrammed
as well [60]. Moreover, skin fibroblasts from proger-
oid syndromes including HGPS and WS can be suc-
cessfully reprogrammed to iPSC [24, 26, 61, 62]. One
of the exciting findings from these reprogramming
experiments is the erasure of aging phenotype origin-
ally associated with premature aging in the progeroid
cells, despite the presence of the disease genotypes in
those cells. Interestingly, premature aging phenotypes,
such as expression of progerin proteins in HGPS and
telomere dysfunction in WS, reappear when repro-
grammed iPSCs are differentiated to somatic and adult
stem cells. These iPSC-based disease models, although
limited to in vitro condition, are useful for studying
the aging mechanism in different adult stem cell
compartments.
Epigenetic reprogramming to iPSC is accompanied
with reactivation of telomerase activity, which is gener-
ally silenced in somatic cells [63]. Telomerase reactiva-
tion is usually found in cancers and ESC. These
immortal cells require telomerase to replenish eroded
telomeres to support active proliferation. Therefore, the
acquisition of telomerase activity during reprogramming
can be regarded as a process of “rejuvenation”.
Intriguingly, iPSCs not only reactivate their telomerase
activity but also acquire telomeric epigenetic marks
characteristic of ESC. This is demonstrated by the de-
creased H3K9 and H4K20 trimethylation and increased
telomere recombination as compared to differentiated
MEF [64]. We also found the restoration of telomere
function during reprogramming in WS cells. This is ac-
complished by two events, the reactivation of telomerase
genes and the expression of shelterin genes [24]. Tel-
omerase activation is beneficial to WRN-deficient cells
as it elongates short telomeres and prevents accelerated
senescence [65]. Secondly, proper expression of shel-
terin genes ensures telomere capping and prevention
of telomere dysfunction. In line with this notion, re-
programmed WS cells do not exhibit premature telo-
mere loss or defective synthesis of sister telomeres at
their lagging strands (these are the two important fea-
tures of WS cells) nor exhibiting premature senes-
cence [24, 26]. In HGPS cells expressing progerin,
reprogramming also silences progerin expression in
HGPS iPSC lines, although it is unknown whether it
is related to telomerase [61].
Telomere reprogramming appears an attractive tool
for reversing aging, including progeria cells [63]. How-
ever, senescence and other aging phenotypes (e.g., gen-
omic instability, abnormal nuclear structure, defective
DNA repair, and accelerated telomere loss) recur as the
pluripotent cells are differentiated to adult stem cells,
limiting the use of these stem cells for regenerative pur-
pose [61]. Genomic editing may provide a solution for
this purpose. Recent advancement in technologies such
as TALEN and CRISPR/Cas9 facilitates precise genetic
engineering for generating mutant or correcting mutant
cells. A number of patient-specific iPSC lines have been
successfully corrected in different disease models to re-
store the normal phenotypes [66]. Currently, monogenic
diseases serve a good model for genetic correction, al-
though the issues on safety and ethics have to be refined
[67]. The majority of WS is monogenic with mutations
found in the WRN locus [68]. Although genetic correc-
tion of WRN has not been reported in WS cells, the
availability of WS iPSC makes this approach possible
[24, 26]. Indeed, restoration of wild-type WRN expres-
sion would rescue the aging-associated phenotypes
caused by WRN deficiency, as demonstrated by multiple
studies that lentiviral/retroviral delivery WRN gene can
rescue the phenotypes [18, 69, 70]. Genetic correction of
WRN may not have a significant beneficial effect on
iPSC and its pluripotency, since the high telomerase ac-
tivity in iPSC appears to “fix” the telomere-associated
problems [24]. However, restoration of wild-type WRN
is beneficial to adult stem cells or differentiated somatic
cells because telomerase activity is greatly reduced in
these cell types, so the role of WRN for maintaining
genomic integrity and stability appears critical. We fore-
see the prospect of utilizing corrected WS iPSC to gen-
erate transplantable adult stem cells such as MSC for
therapeutic purpose. Such approach holds two advan-
tages. One is the global erasure of aging epigenetic
marks and telomere reprogramming during integration-
free and safe iPSC generation. The other one is the
correction of disease-causing gene in pluripotent state
rather than in more differentiated cells because clonal
selection and expansion require substantial cell prolifer-
ation, which is telomere-sensitive.
Recent advances in anti-aging research
Progeroid syndromes share many similarities to natural
aging, despite the different causes and origins driving
the aging process. Reversal of aging through epigenetic
reprogramming is still technically challenging. Anti-
aging research on natural aging may also help develop-
ing drugs for treating premature aging diseases (Fig. 2).
For example, vitamin C is generally used as an anti-
oxidant for anti-aging. Moreover, it is shown to change
the aging signaling pathway and improve healthy aging
in the liver of a mouse model for WS [71]. Interestingly,
the role of vitamin C is more than merely an anti-
oxidant. It is surprisingly found to boost reprogramming
of somatic cells to iPSC by alleviating senescence [72].
Vitamin C is later known to reduce the epigenetic bar-
rier through regulating histone demethylases Jhdm1a/1b
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and DNA demethylation-related enzyme Tet1; both
classes are critical epigenetic enzymes for reprogram-
ming and senescence [73, 74]. The beneficial effect of
vitamin C thus is not only limited to its anti-oxidation
activity but also its ability to reset the aging-associated
epigenetic marks. Adult WS patients mostly develop
type 2 diabetes mellitus. Antidiabetic drugs like metfor-
min, biguanide, and thiazolidinediones have been re-
ported to improve insulin sensitivity in WS patients
[75–77]. In addition to improve diabetes, metformin
plays a second role in extending lifespan, as shown in
animal models and clinical trials [78, 79]. Resveratrol, a
natural product for anti-aging research, is also shown to
improve insulin-resistant hyperglycemia and fatty liver
in Wrn mutant mice, although with undesired side
effects such as increased frequency of lymphoma and
solid tumors [80]. Small molecules such as the
SB203580 compound that inhibits the p38 MAPK sig-
naling can ameliorate premature senescence in WS fi-
broblasts [81]. Such inhibitors are still in clinical
trials. A number of anti-aging approaches have been
recently discovered to improve healthy aging. These
approaches, though they have not been experimentally
and clinically tested for WS, may have therapeutic
benefit on progeroid syndromes. For instance, age-
related mitochondrial dysfunction (another hallmark
of aging) is coupled with reduced nuclear NAD+ level,
the process of which is dependent on SIRT1. Interest-
ingly, increasing the NAD+ level in old mice restores
mitochondrial function to a youthful state, raising the
Fig. 2 Drugs that improve aging cells. Resveratrol and NAD+ are known to improve mitochondrial dysfunction associated with aging, whereas
vitamin C is an anti-oxidant for scavenging ROS as well as its additional role in epigenetic control. SB203580 is a p38 inhibitor that prevents
premature senescence. Other compounds that have been shown to improve healthy aging may also benefit progeroid cells. Senolytics are drugs
that selectively remove senescent cells, whereas rapamycin and metformin increase lifespan by targeting the mTOR pathway. Unknown factors
from young blood may also improve aging in various organs
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opportunity to reverse aging by modulating the mito-
chondrial function [82]. Senescence, an irreversible
cell cycle arrest, is a driving force for organismal
aging. Accumulation of senescence in an adult stem
cell compartment is harmful to normal stem cells for
their functions in differentiation, re-entering quies-
cence, and self-renewal. Inflammatory cytokines se-
creted from senescent cells also have a systemic effect
on the pro-aging process [83]. Hence, removal of sen-
escent cells is beneficial and has been demonstrated
in model animals [84]. Drugs that selectively induce
death of senescent cells may serve as an appealing al-
ternative approach. A combination of drugs (dasatinib
and quercetin) collectively termed senolytics is able to
eliminate senescent cells in chronologically aged and
progeroid Ercc1−/Δ mice, thus improving cardiac func-
tion and delaying the pathogenic symptoms [85]. It is
exciting to see how such compounds can be translated
into clinical uses and evaluation of safety. Recently, reju-
venation through the exchange of “youthful” factors from
young blood is being underscored for the significance
[86]. It was firstly demonstrated in a parabiotic pairing of
young and old mice that share their circulatory system.
This heterochronic parabiosis system improves stem
cell function in multiple organs including the muscle,
liver, heart, spinal cord, and even brain. Components
from young blood help reverse age-related decline in
skeletal muscle stem cells, cardiac hypertrophy, and
improve cognitive function possibly through enhanced
neurogenesis [87–92]. It remains largely unknown
what “rejuvenation” factor(s) is responsible for such
beneficial effect. Nevertheless, clinical trials using young
blood have been approved for testing in people with
Alzheimer’s disease and perhaps for progeroid syndromes
in the future.
Concluding remarks
Understanding the molecular mechanism driving adult
stem cell aging will help us design drugs for combating
aging. Progeroid syndromes are good models since the
disrupted genetic pathways related to aging have been
well studied. It is worth noting that biological aging is a
consequence of multiple factors, each with its import-
ance. This review only highlights the importance of telo-
mere function and epigenetic regulation in WS because
of the nature of the WRN helicase involved in these
pathways. Other pathways such as ROS production, pro-
tein homeostasis, and mitochondrial dysfunction are
equally important. Moreover, the aging mechanism of
stem cells in different disease models does not com-
pletely overlap. The molecular mechanism leading to
HGPS, for instance, is not identical to WS, although
many similarities are found (e.g., epigenetic changes and
accelerated senescence in mesenchymal cells). A more
detailed comparison between different segmental proger-
oid syndromes can be found in other reviews [9, 93, 94].
To conclude, recent breakthroughs in studying age-
associated diseases open new avenues to improve human
health by targeting the aging pathways.
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